Scientific Papers

Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis | Systematic Reviews

Description of Image

  • Inusa B, Hsu L, Kohli N, et al. Sickle cell disease—genetics, pathophysiology, clinical presentation and treatment. IJNS. 2019;5:20.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wastnedge E, Waters D, Patel S, et al. The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. J Glob Health. 2018;8:021103.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sedrak A, Kondamudi NP. Sickle cell disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2023. http://www.ncbi.nlm.nih.gov/books/NBK482384/. Accessed 14 Mar 2023.

  • Opoka RO, Ndugwa CM, Latham TS, et al. Novel use of hydroxyurea in an African Region with malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 2017;130:2585–93.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Serjeant GR. The clinical features of sickle cell disease. Baillière’s Clinical Haematology. 1993;6:93–115.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kulozik AE, Wainscoat JS, Serjeant GR, et al. Geographical survey of βS-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation. Am J Hydroxyuream Genet. 1986;39:239–44.

    CAS 

    Google Scholar
     

  • Mukherjee MB, Nadkarni AH, Gorakshakar AC, Ghosh K, Mohanty D, Colah RB. Clinical, hematologic and molecular variability of sickle cell-β thalassemia in western India. Indian J Hydroxyuream Genet. 2010;16:154–8.

    Article 
    CAS 

    Google Scholar
     

  • Mukherjee MB, Lu CY, Ducrocq R, et al. Effect of alpha-thalassemia on sickle-cell anemia linked to the Arab-Indian haplotype in India. Am J Hematol. 1997;55:104–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Pandey S, Pandey S, Mishra RM, Sharma M, Saxena R. Genotypic influence of α-deletions on the phenotype of Indian sickle cell anemia patients. Korean J Hematol. 2011;46:192–5.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pandey SK, Pandey S, Ranjan R, et al. Phenotypic effect of α-globin gene numbers on Indian sickle β-thalassemia patients. J Clin Lab Anal. 2014;28:110–3.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123:377–90.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hebbel RP, Belcher JD, Vercellotti GM. The multifaceted role of ischemia/reperfusion in sickle cell anemia. J Clin Invest. 2020;130:1062–72.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Allali S, Taylor M, Brice J, de Montalembert M. Chronic organ injuries in children with sickle cell disease. Haematologica. 2021;106:1535–44.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus. 2014;30:91–6.

    Article 
    PubMed 

    Google Scholar
     

  • McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14:1749–58.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–48.

    Article 
    PubMed 

    Google Scholar
     

  • Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118:4985–91.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HYDROXYUREAG trial. Blood. 2012;120:4304–10.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • John CC, Opoka RO, Latham TS, et al. Hydroxyurea dose escalation for sickle cell anemia in Sub-Saharan Africa. N Engl J Med. 2020;382:2524–33.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–84.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behavior Research Methods. 2009;41:1149–60.

    Article 
    PubMed 

    Google Scholar
     

  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Thornburg CD, Dixon N, Burgett S, et al. A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer. 2009;52:609–15.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hankins JS, McCarville MB, Rankine-Mullings A, et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. Am J Hematol. 2015;90:1099–105.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rankine-Mullings A, Reid M, Soares D, et al. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. Br J Haematol. 2021;195:612–20.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wang WC, Zou P, Hwang SN, et al. Effects of hydroxyurea on brain function in children with sickle cell anemia. Pediatr Blood Cancer. 2021;68:e29254.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zimmerman SA, Schydroxyurealtz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood. 2007;110:1043–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ware RE, Davis BR, Schydroxyurealtz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387:661–70.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer. 2006;47:894–900.

    Article 
    PubMed 

    Google Scholar
     

  • Peine BR, Callaghan MU, Callaghan JH, Glaros AK. Prophylactic hydroxyurea treatment is associated with improved cerebral hemodynamics as a surrogate marker of stroke risk in sickle cell disease: a retrospective comparative analysis. J Clin Med. 2022;11:3491.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Adegoke SA, Macedo-Campos R de S, Braga JAP, Figueiredo MS. Changes in transcranial doppler flow velocities in children with sickle cell disease: the impact of hydroxyurea therapy. J Stroke Cerebrovasc Dis. 2018;27:425–31.

    Article 
    PubMed 

    Google Scholar
     

  • Estepp JH, Cong Z, Agodoa I, et al. What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study. Br J Haematol. 2021;194:463–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ghafuri DL, Chaturvedi S, Rodeghier M, et al. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia. Pediatr
    Blood Cancer 2017; 64.:https://doi.org/10.1002/pbc.26401.

  • Lagunju IA, Labaeka A, Ibeh JN, Orimadegun AE, Brown BJ, Sodeinde OO. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort. Pediatr Blood Cancer. 2021;68:e28906.

    Article 
    PubMed 

    Google Scholar
     

  • Hankins JS, Helton KJ, McCarville MB, Li C-S, Wang WC, Ware RE. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer. 2008;50:293–7.

    Article 
    PubMed 

    Google Scholar
     

  • Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001;139:790–6.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Abdullahi SU, Wudil BJ, Bello-Manga H, et al. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial. PediatrHematol Oncol. 2021;38:49–64.


    Google Scholar
     

  • Nottage KA, Ware RE, Aygun B, et al. Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia. Br J Haematol. 2016;175:331–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tavakkoli F, Nahavandi M, Wyche MQ, Castro O. Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study. Clin Ther. 2005;27(7):1083–8. https://doi.org/10.1016/j.clinthera.2005.07.002.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Karkoska K, Quinn CT, Niss O, Pfeiffer A, Dong M, Vinks AA, McGann PT. Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia. Am J Hematol. 2021;96(5):538–44. https://doi.org/10.1002/ajh.26120. (Epub 2021 Feb 19).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kapustin D, Leung J, Odame I, Williams S, Shroff M, Kassner A. Hydroxycarbamide treatment in children with Sickle Cell Anaemia is associated with more intact white matter integrity: a quantitative MRI study. Br J Haematol. 2019;187(2):238–45. https://doi.org/10.1111/bjh.16063. (Epub 2019 Jun 18 PMID: 31215028).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Puffer E, Schatz J, Roberts CW. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease. Child Neuropsychol. 2007;13(2):142–54. https://doi.org/10.1080/09297040600584626.

    Article 
    PubMed 

    Google Scholar
     

  • Grace RF, Su H, Sena L, Poussaint TY, Heeney MM, Gutierrez A. Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. Am J Hematol. 2010;85(2):135–7. https://doi.org/10.1002/ajh.21596.

    Article 
    PubMed 

    Google Scholar
     

  • Alvarez O, Miller ST, Wang WC, et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HYDROXYUREAG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer. 2012;59:668–74.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Aygun B, Mortier NA, Smeltzer MP, Shydroxyurealkin BL, Hankins JS, Ware RE. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol. 2013;88:116–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hankins JS, Aygun B, Nottage K, et al. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Medicine (Baltimore). 2014;93: e215.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Silva Junior GB, Vieira APF, Couto Bem AX, et al. Proteinuria in adults with sickle-cell disease: the role of hydroxycarbamide(hydroxyurea) as a protective agent. Int J Clin Pharm. 2014;36:766–70.

    Article 
    PubMed 

    Google Scholar
     

  • Bartolucci P, Habibi A, Stehlé T, et al. Six months of hydroxyurea reduces albuminuria in patients with sickle cell disease. J Am Soc Nephrol. 2016;27:1847–53.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Laurin L-P, Nachman PH, Desai PC, Ataga KI, Derebail VK. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. Nephrol Dial Transplant. 2014;29:1211–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lebensburger J, Johnson SM, Askenazi DJ, Rozario NL, Howard TH, Hilliard LM. Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia. Am J Hematol. 2011;86:430–2.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Opoka RO, Hydroxyureame HA, Latham TS, et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica. 2020;105:e272–5.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Silva Junior GB, Libório AB, Vieira APF, et al. Evaluation of renal function in sickle cell disease patients in Brazil. Braz J Med Biol Res. 2012;45:652–5.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • McKie KT, Hanevold CD, Hernandez C, Waller JL, Ortiz L, McKie KM. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. J PediatrHematol Oncol. 2007;29:140–4.

    CAS 

    Google Scholar
     

  • Tehseen S, Joiner CH, Lane PA, Yee ME. Changes in urine albumin to creatinine ratio with the initiation of hydroxyurea therapy among children and adolescents with sickle cell disease. Pediatr Blood Cancer 2017; 64. https://doi.org/10.1002/pbc.26665.

  • Santos A, Pinheiro V, Anjos C, et al. Scintigraphic follow-up of the effects of therapy with hydroxyurea on splenic function in patients with sickle cell disease. Eur J Nucl Med Mol Imaging. 2002;29:536–41.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Nottage KA, Ware RE, Winter B, et al. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. Eur J Haematol. 2014;93:377–83.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood. 1996;88:1951–3.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HYDROXYUREASOFT extension study. Blood. 2005;106:2269–75.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HYDROXYUREAG). Lancet. 2011;377:1663–72.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rai P, Joshi VM, Goldberg JF, et al. Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia. Blood Adv. 2021;5:89–98.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Olnes M, Chi A, Haney C, et al. Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. Am J Hematol. 2009;84:530–2.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yates AM, Joshi VM, Aygun B, et al. Elevated tricuspid regurgitation velocity in congenital hemolytic anemias: prevalence and laboratory correlates. Pediatr Blood Cancer. 2019;66:e27717.

    Article 
    PubMed 

    Google Scholar
     

  • Desai PC, May RC, Jones SK, et al. Longitudinal study of echocardiography-derived tricuspid regurgitant jet velocity in sickle cell disease. Br J Haematol. 2013;162:836–41.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. Br J Haematol. 2009;144:736–41.

    Article 
    PubMed 

    Google Scholar
     

  • Garadah T, Mandeel F, Jaradat A, Bin TK. The effects of hydroxyurea therapy on the six-minute walk distance in patients with adult sickle cell anemia: an echocardiographic study. J Blood Med. 2019;10:443–52.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Adekile AD, Gupta R, Al-Khayat A, Mohammed A, Atyani S, Thomas D. Risk of avascular necrosis of the femoral head in children with sickle cell disease on hydroxyurea: MRI evaluation. Pediatr Blood Cancer. 2019;66:e27503.

    Article 
    PubMed 

    Google Scholar
     

  • Mahadeo KM, Oyeku S, Taragin B, et al. Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease. Am J Hematol. 2011;86:806–8.

    Article 
    PubMed 

    Google Scholar
     

  • Estepp JH, Smeltzer MP, Wang WC, Hoehn ME, Hankins JS, Aygun B. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. Br J Haematol. 2013;161:402–5.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • McLaren A, Klingel M, Behera S, Odame I, Kirby-Allen M, Grasemann H. Effect of hydroxyurea therapy on pulmonary function in children with sickle cell anemia. Am J Respir Crit Care Med. 2017;195(5):689–91.

    Article 
    PubMed 

    Google Scholar
     

  • Kotwal N, Pillai DK, Darbari DS, Sun K, Koumbourlis AC. Spirometric changes after initiation of hydroxyurea in children with sickle cell anemia. J Pediatr Hematol Oncol. 2022;44(6):e923–5.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Afangbedji N, Jerebtsova M. Glomerular filtration rate abnormalities in sickle cell disease. Front Med (Lausanne). 2022;9:1029224.

    Article 
    PubMed 

    Google Scholar
     

  • Description of Image

    Source link